The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Nektar Therapeutics's revenues will expand 53.3% and EPS will remain in the red.
The average estimate for revenue is $27.5 million. On the bottom line, the average EPS estimate is -$0.43.
Last quarter, Nektar Therapeutics reported revenue of $21.1 million. GAAP reported sales were 34% higher than the prior-year quarter's $15.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at -$0.46. GAAP EPS were -$0.46 for Q4 compared to -$0.33 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 65.5%, much about the same as the prior-year quarter. Operating margin was -205.1%, 380 basis points worse than the prior-year quarter. Net margin was -250.3%, much worse than the prior-year quarter.
The full year's average estimate for revenue is $202.6 million. The average EPS estimate is -$1.05.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 195 members out of 223 rating the stock outperform, and 28 members rating it underperform. Among 52 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 40 give Nektar Therapeutics a green thumbs-up, and 12 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Nektar Therapeutics is outperform, with an average price target of $11.29.
- Add Nektar Therapeutics to My Watchlist.